/2025 Annual Shareholders Meeting Materials

NEWS

2025 Annual Shareholders Meeting Materials

Shanghai Stock Exchange

2026/05/08

Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials Securities code: 688302 Securities abbreviation: Haichuang Pharmaceutical Haichuang Pharmaceutical Co., Ltd.

May 2026

Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials

4. The meeting will review and vote on resolutions in the order listed in the meeting notice.

Shareholders (including shareholders’ agents, the same below) participating in shareholders’ meetings shall enjoy the rights to speak, question, vote and other rights in accordance with the law. Shareholders who fail to pass the shareholder qualification review or enter the venue after the host announces the start of the meeting will not have the right to vote at this on-site meeting, and other rights will not be affected. Shareholders participating in a shareholders' meeting should conscientiously exercise and perform their legal rights and obligations, and must not infringe on the legitimate rights and interests of other shareholders or disrupt the normal order of the meeting.
If shareholders and their agents request to speak at the on-site shareholders' meeting, they should register with the company's board of directors office before the appointment registration date for attending the on-site meeting. The meeting host arranges speeches according to the list and order provided by the conference affairs team.

Shareholders and shareholders' agents who request to speak on site should raise their hands in accordance with the agenda of the meeting, and can speak only with the permission of the host of the meeting. When multiple shareholders and shareholder agents request questions at the same time, the person who raises his hand first will speak first; if the order cannot be determined, the moderator will designate the speaker. Shareholders who temporarily request to speak will be placed after shareholders who register to speak.

During the meeting, only shareholders and their agents will be allowed to speak or ask questions. Speeches or questions should focus on the topics of this meeting, be concise and to the point, and should not exceed 5 minutes. When speaking or asking questions, the name of the shareholder and the total number of shares held must be stated. Each shareholder and shareholder's agent may speak or ask questions no more than 2 times. If you want to know more about the company beyond the scope of the topic, you can consult the secretary of the company's board of directors after the meeting.
When shareholders request to speak, they shall not interrupt the meeting reporter’s report or the speeches of other shareholders. After the voting on the resolution begins, the meeting will no longer arrange for shareholders to speak. If a shareholder violates the above provisions, the host of the meeting has the right to refuse or stop him.
The host can arrange for company directors and senior managers to answer questions raised by shareholders. The host or his designated relevant personnel have the right to refuse to answer questions that may reveal the company's trade secrets and/or inside information and harm the common interests of the company and shareholders.
This shareholders’ meeting will adopt a combination of on-site voting and online voting. Proposals at the shareholders' meeting are voted on by registered vote. Shareholders exercise their voting rights based on the number of voting shares they represent, and each share is entitled to one vote. The company will issue an announcement on the shareholders' meeting resolutions based on the results of on-site voting and online voting.
All proposals of the shareholders' meeting are listed on the same voting ticket. Shareholders attending the shareholders' meeting should express one of the following opinions on the proposals submitted for voting: agree, oppose or abstain. Shareholders present on site are required to fill in the form item by item as required, and be sure to sign the name of the shareholder. If the form is not filled in, filled in too much, filled in incorrectly, has illegible handwriting, does not have the signature of the voter or does not vote, it will be deemed as "abstention".
In order to ensure the solemnity and normal order of the shareholders' meeting, the company has the right to refuse entry to the venue in accordance with the law, except for shareholders and shareholders' agents present at the meeting, company directors, senior executives, retained lawyers and persons invited by the board of directors.
This meeting will be witnessed on-site by a practicing lawyer from a law firm hired by the company and a legal opinion will be issued.
During the meeting, participants should pay attention to maintaining order in the venue, do not move around at will, set their mobile phones to silent mode, and refuse personal recording, video and photography. Meeting staff have the right to stop any behavior that interferes with the normal proceedings of the meeting, provokes trouble or infringes on the legitimate rights and interests of other shareholders, and reports to the relevant departments for handling. Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials
The company does not distribute gifts to shareholders who attend the shareholders' meeting, nor is it responsible for arranging the accommodation of shareholders who attend the shareholders' meeting, etc., and treats all shareholders on an equal basis.
For the specific content of the registration method and voting method of this shareholders' meeting, please refer to the "Notice of Haichuang Pharmaceutical Co., Ltd. on convening the 2025 Annual Shareholders' Meeting" (announcement number: 2026-016) disclosed by the company on the website of the Shanghai Stock Exchange (http://www.sse.com.cn) on April 25, 2026.

Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials

Haichuang Pharmaceutical Co., Ltd.

2025 Annual Shareholders Meeting Agenda

1. Meeting time, location and voting method

(1) On-site meeting time: 14:00 on May 15, 2026 (Friday)

(2) On-site meeting location: Company Conference Room on the 4th floor, Building 1, Rongyao Building, No. 5 Keyuan South Road, High-tech Zone, Chengdu City, Sichuan Province

(3) Meeting convener: Board of Directors of Haichuang Pharmaceutical Co., Ltd.

(4) Meeting host: Chairman YUANWEI CHEN (Chen Yuanwei)

(5) Participants: shareholders or their authorized representatives, directors, board secretaries, and witnessing lawyers who are registered on the equity registration date shall attend the meeting, and senior managers shall attend the meeting as non-voting delegates

(6) Online voting system: Shanghai Stock Exchange Shareholders Meeting online voting system

(7) Voting method: This shareholders' meeting will adopt a voting method that combines on-site voting and online voting. For details, please refer to the "Notice of Haichuang Pharmaceutical Co., Ltd. on Convening the 2025 Annual Shareholders' Meeting" issued by the company (Announcement No.: 2026-016)

2. Meeting Agenda

(1) Participants sign in, receive meeting materials, and shareholders register to speak

(2) The host delivers a welcome speech, announces the start of the meeting, and reports to the meeting the number of shareholders attending the on-site meeting, the number of voting rights they hold, and the ratio of the number of voting rights held to the number of voting rights of the company.

(3) The host reads out the meeting instructions

(4) Recommend vote counting and scrutinizing members

(5) Consider each proposal item by item

Voting shareholder type serial number Proposal name

Non-cumulative voting resolution for A-share shareholders

1 Proposal on the company’s “2025 Annual Report” and its summary √

Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders' Meeting Materials 2 Proposal on the company's "2025 Board of Directors Work Report" √ 3 Proposal on the company's "2025 Financial Final Account Report" √ 4 Proposal on the company's "2025 Profit Distribution Plan" √ 5 Proposal on the company's directors' 2026 remuneration (allowance) plan √ 6 Regarding the renewal of the company's 2026 annual financial report and internal control audit √

agency motion

7 Regarding the proposal to the shareholders’ meeting to authorize the board of directors to use simplified procedures to specific parties √

bill to issue shares

8 About purchasing liability insurance for the company, directors and senior managers √

motion

9 Proposal on formulating the company’s “Remuneration Management System for Directors and Senior Management Personnel” √

(6) The meeting listened to the "2025 Work Report of Independent Directors" and "2026 Remuneration Plan for Senior Management of the Company"

(7) In response to the resolutions reviewed at the meeting, shareholders and shareholders’ agents made speeches and asked questions

(8) Shareholders and shareholders’ proxies present at the meeting vote on various proposals

(9) Adjourn the meeting and tally the voting results

(10) The meeting resumes and the moderator announces the voting results.

(11) The host reads out the resolutions of the shareholders’ meeting

(12) Witness the lawyer reading out the legal opinion

(13) Signing meeting documents

(14) The host announces the end of the meeting

Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials Haichuang Pharmaceutical Co., Ltd.

2025 Annual Shareholders Meeting Proposal

Proposal 1. Proposal on the company's "2025 Annual Report" and its summary

Dear shareholders and shareholders’ agents:

The "2025 Annual Report" and "2025 Annual Report Summary" of Haichuang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") have been reviewed and approved at the 17th meeting of the company's second board of directors, and will be published and disclosed on the website of the Shanghai Stock Exchange (www.sse.com.cn) on April 25, 2026.

It is now submitted to the shareholders' meeting for review. All shareholders and shareholders' agents are requested to review this document.

Board of Directors of Haichuang Pharmaceutical Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Haichuang Pharmaceutical Co., Ltd. on May 15, 2026

Proposal 2. Proposal on the company's "2025 Board of Directors Work Report"

Dear shareholders and shareholders’ agents:

In accordance with the "Company Law" and other laws and regulations, as well as the relevant provisions of the "Articles of Association" and "Rules of Procedure of the Board of Directors", the company's board of directors conscientiously performed the various responsibilities entrusted to the board of directors by the "Company Articles of Association" in 2025, ensured the company's scientific decision-making, strictly implemented various resolutions passed by the shareholders' meeting, promoted the smooth and orderly development of various businesses, and promoted the company's standardized operations. The company's board of directors summarized the main work of the board of directors in 2025 and submitted the company's "2025 Board of Directors Work Report". Please see Appendix 1 for details.

This proposal has been reviewed and approved at the 17th meeting of the company's second board of directors and is now submitted to the shareholders' meeting for review. All shareholders and shareholders' agents are requested to review this document.

Board of Directors of Haichuang Pharmaceutical Co., Ltd.

May 15, 2026

Attachment 1: "2025 Board of Directors Work Report"

Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials

Attachment 1

Haichuang Pharmaceutical Co., Ltd.

2025 Annual Board of Directors Work Report

In 2025, the company's board of directors strictly complied with the provisions and requirements of relevant laws, regulations, normative documents and company systems such as the Company Law, Securities Law, Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules, Articles of Association, and Rules of Procedure of the Board of Directors, and worked diligently and conscientiously to implement various resolutions passed by the shareholders' meeting to promote the company's steady development. The work report of the company’s board of directors in 2025 is now as follows:

1. The company’s main operations in 2025

The company is an innovation-driven international innovative pharmaceutical company. The company relies on core platforms such as the Targeted Protein Degradation (TPD) technology platform (including PROTAC technology, molecular glue degradation technology, etc.), deuterium technology and translational medicine technology platforms. It focuses on cancer, metabolic diseases, autoimmune diseases/chronic inflammation and other treatment areas with significant market potential and urgent clinical needs, and is deeply involved in the full-cycle research and development of innovative drugs from early drug development to late-stage commercialization. In May 2025, the company's first self-developed Category 1 new drug for the treatment of advanced prostate cancer, Hainaan® (generic name: Deuterated Enzalutamide Soft Capsules), was approved for marketing by the State Food and Drug Administration, and was included in the National Medical Insurance Drug Catalog in December 2025 (officially effective from January 1, 2026). During the reporting period, the product achieved sales revenue of 20.1925 million yuan, making substantial progress in the commercialization process. The company's R&D projects are advancing in an orderly manner, the talent echelon continues to be strengthened, and outstanding talents continue to join. The company's core management and R&D teams are stable and have rich experience in the field of innovative drug R&D. At the same time, the company's cash reserves are in good condition, ensuring the continued development of research and development and business. During the reporting period, the company continued to promote the construction of production bases and the improvement of production quality management systems to support closed-loop operations from research and development to commercialization. As of the date of this report, the company's soft capsule production line has successfully passed the GMP compliance inspection and established a production quality system that complies with international standards, laying a solid foundation for sustained and stable product supply and long-term development.

During the reporting period, the company's various tasks were progressed smoothly and a number of milestones were achieved. The key work details are as follows:

(1) The first new drug, deuterated enzalutamide soft capsules, was approved for marketing, marking a key breakthrough in the commercialization process

During the reporting period, the company continued to maintain active communication with regulatory agencies and made every effort to promote the review and approval of new drug marketing applications, and ushered in an important milestone in May 2025 - the independently developed Class 1 new drug "Deuterated Enzalutamide Soft Capsules" was officially approved for marketing by the National Medical Products Administration for the treatment of metastatic castration. 2025 Annual Shareholders Meeting Materials of Haichuang Pharmaceutical Co., Ltd.

Resistant prostate cancer (mCRPC). This product is the first domestic innovative drug approved for marketing in China for the treatment of this indication. Its successful launch marks a key leap forward for the company in the commercialization of innovative drugs.

Clinical research data shows that China's phase III clinical study of deuterated enzalutamide (HC-1119) achieved the primary endpoint. Compared with the control group, deuterated enzalutamide significantly prolonged the patient's progression-free survival (PFS) and reduced the risk of disease progression or death by 42% (HR=0.58, 95%CI: 0.439-0.770; p=0.0001). Compared with other new endocrine drugs, deuterated enzalutamide soft capsules have excellent safety performance and can significantly reduce the incidence of central nervous system adverse events (such as epilepsy, falls, etc.) without rash-related adverse reactions, while reducing the risk of common complications in elderly patients.

During the reporting period, the company simultaneously and actively promoted commercialization work. By formulating a four-wheel drive strategy of "medicine-market-access-sales" and adopting a model that combines self-built teams with external cooperation, the company has quickly built a nationwide commercial channel network. In June 2025, the product was shipped nationwide and the first prescription was issued. Patients can purchase the drug at DTP pharmacies in major provincial capital cities across the country with a doctor's prescription. This marks that this domestically produced innovative drug with independent intellectual property rights has officially entered the clinical application stage, providing a new treatment option for Chinese prostate cancer patients.

As of the end of the reporting period, Deuterated Enzalutamide Soft Capsules had achieved drug sales revenue of 20.1925 million yuan, and the commercialization process was progressing in an orderly manner.

(2) Establish a professional commercialization system and accelerate market penetration

During the reporting period, the company systematically promoted commercialization capability building. Before the product is launched, a commercialization team with industry competitiveness has been established. Its core members all have backgrounds in leading pharmaceutical companies at home and abroad. They also have commercialization experience in leading the entire process of new drug launch and academic promotion in domestic innovative drug companies. The company adopts a "self-operation + investment promotion" cooperation model to quickly cover core markets. The self-operated team focuses on covering key academic provinces, key hospitals and TOP KOLs across the country. Through professional academic promotion, with evidence-based medical evidence as the core, and by constructing a "clinical value narrative", drug information is transformed into a trustworthy academic discourse for doctors. It achieves precise coupling of scientific communication and commercial goals within a compliance framework, and shapes the brand awareness of "Deuterated Enzalutamide", thus influencing and driving the establishment of brand concepts in self-operated and agent cooperation regions. The cooperation partners of the investment team are all local agents with terminal access and market coverage advantages. These agents also have rich promotion experience in specialty drugs and urology, forming complementary advantages with the self-operated team.

During the reporting period, in terms of academic promotion, deuterated enzalutamide appeared at the 2025 Pujiang Prostate Cancer Academic Conference, the 32nd Urology Branch of the Chinese Medical Association (CUA) Academic Conference, and the 2025 Bihaichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials of Six Provinces and One City in East China

We have participated in more than 220 academic exchanges at all levels in academic activities such as the Urological Surgery Academic Annual Conference and the Urology Branch of the Jiangxi Medical Association and the 2025 Urology Branch of the Shanghai Medical Doctors Association. Through academic exchanges, we objectively convey the clinical value and research results of drugs and help clinicians understand product characteristics.

During the reporting period, in terms of medicine, deuterated enzalutamide has been included in the "CSCO Guidelines for the Diagnosis and Treatment of Prostate Cancer" (2025 Edition), and deuterated enzalutamide has received multiple recommendations. The CSCO guideline gave deuterated enzalutamide a high-level recommendation, which is not only an authoritative recognition of its clinical value and innovation, but also will provide solid academic support for the product's clinical prescription and market access, help enhance clinical medication confidence, and promote the widespread application of drugs in the field of prostate cancer treatment. The company is conducting IIT/RWE to accumulate real-world data and explore some preliminary efficacy in the entire course of prostate cancer (such as perioperative or mHSPC).

During the reporting period, in terms of market access, the company actively prepared for and participated in the 2025 national medical insurance negotiations. After full preparation and orderly advancement, deuterated enzalutamide has successfully passed the national negotiations and was officially included in the "National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalog (2025)" (effective from January 1, 2026). In the future, the company will actively cooperate with the implementation of medical insurance policies, accelerate the recruitment and procurement network and dual-channel pharmacy access in various provinces and cities, continue to expand drug purchase channels, and improve drug accessibility for patients. The company will also continue to carry out professional academic promotion, continue to build product brand awareness and clinical recognition, and benefit more Chinese prostate cancer patients.

(3) The R&D pipeline is advanced in an orderly manner, and core projects have achieved milestones.

In 2025, the company will continue to focus on the research and development of innovative drugs and optimize the research and development process and management efficiency. Against the background of adjustments to R&D investment throughout the year, the company's core pipeline under development still maintains orderly progress, with multiple key projects achieving key milestones. Among them, the company's core product deuterated enzalutamide soft capsules have been approved for marketing by the National Medical Products Administration, marking the company's important achievements in independent research and development and transformation of innovative drugs. The remaining pipelines under development are also progressing smoothly, gradually forming an orderly product echelon: In May 2025, the Australian phase I clinical study results of HP518 were published in the international journal "Investigational New Drugs". The Chinese phase II clinical trial of HP518 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) has completed the enrollment of all participants. In November 2025, HP518 The phase Ib/II clinical trial of tablets combined with anti-tumor drugs for the treatment of advanced prostate cancer was approved by China's NMPA, further expanding the clinical development path of this drug. HP515 has completed China's Phase I clinical trial for the treatment of metabolic-associated steatohepatitis (MASH). Preliminary data show that the drug's safety, exposure, and pharmacodynamics are in line with expectations. As of the disclosure date of this report, all participants in its Phase IIa clinical trial in China have been enrolled. In addition, in the field of obesity, HP515 combined with GLP-1R agonist is used in Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials

The preclinical research data on obesity were presented in the form of an oral report at the 2025 European Congress on Obesity (ECO), and a poster presentation was conducted at The 3rd Obesity & Weight Loss Drug Development Summit ("The 3rd Annual Obesity and Weight Loss Drug Development Summit"), which has gained the attention and recognition of the international academic community.

While promoting the progress of existing pipelines, the company is also actively carrying out new project evaluation and source innovation research, and continues to consolidate R&D reserves. The company used molecular glue degradation technology to develop VAV1 targets for autoimmune diseases and successfully developed the VAV1 molecular glue degrader preclinical PCC compound HP570. The systematic advancement of the company's R&D pipeline and the accumulation of phased results have laid a solid foundation for building a sustainably competitive product portfolio and achieving long-term steady development.

(4) Strengthen the construction of production capacity and quality system to ensure full chain coordination

In order to meet the needs of commercial production of products, the company has built a modern preparation production factory that complies with GMP standards and is equipped with automated production equipment, precision testing instruments, a complete quality control system and standardized warehousing and logistics facilities. During the reporting period, the company has completed the debugging, trial production and process verification of the soft capsule production line and multi-functional production line equipment in the R&D and production base, and has steadily promoted the construction of the quality management system (GMP).

At the end of January 2026, the production workshop and related production lines of the anti-tumor drug deuterated enzalutamide soft capsules at the company's R&D and production base successfully passed the pharmaceutical GMP compliance inspection, indicating that the workshop's production quality management system complies with the requirements of the "Good Manufacturing Practice for Pharmaceutical Products" and related appendices, and can continuously and stably produce drugs that meet the intended use and registration requirements, providing reliable protection for patient medication safety and efficacy.

During the same period, the company completed changes to the relevant production scope of the "Drug Production License" (A Certificate), further expanding the scope of production qualifications and capabilities, which is conducive to optimizing the production structure, ensuring stable supply, and better meeting future market demand.

In terms of R&D and production base construction, during the reporting period, the company completed a number of special acceptance inspections for R&D and production bases such as high and low voltage power distribution, environmental protection (including soil and groundwater), sewage discharge permits, lightning devices, environmental noise, air quality testing, project safety evaluation, multi-test integration, exhaust gas treatment, and special elevator equipment. As of the disclosure date of this report, the R&D and production base has completed quality acceptance and preliminary fire protection acceptance.

Through the above measures, the company has not only established a quality management system that complies with international standards, but also further strengthened its full-chain collaboration capabilities from R&D, production to commercialization, laying a solid production and quality foundation to ensure stable product supply and support long-term business development.

(5) Deepen global layout and work together to develop overseas markets

Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials

The company adopts a global synchronized development strategy to target major global pharmaceutical markets. At present, the company has established branches in the United States and Australia, built a clinical team with rich international experience, and significantly strengthened the operation and management capabilities of overseas clinical trials. In order to enhance the professional coordination of global R&D, the company hired Dr. Li Ximing as the chief medical officer (CMO) during the reporting period. He will be fully responsible for the company's global clinical development and medical affairs, further consolidating the company's global clinical R&D layout.

In terms of international cooperation, the company actively expands multiple cooperation channels and explores various forms including commercial rights authorization. It plans to carry out strategic collaboration with multinational pharmaceutical companies to jointly promote the development and commercialization of independently developed products in overseas markets and provide safe and effective innovative drugs to more patients around the world. In March 2025, the company signed an overseas strategic cooperation agreement with Sinovac Biopharmaceutical Co., Ltd. The two parties will reach in-depth cooperation around the international market development of cooperative products and jointly promote domestic innovative drugs to go global.

(6) Improve the governance structure and implement the concept of sustainable development

The company continues to optimize its governance system, deepens its understanding and implementation of laws and regulations such as the Company Law, Securities Law, and Measures for the Administration of Information Disclosure of Listed Companies, continuously improves the quality of information disclosure and investor relations management, and effectively safeguards the legitimate rights and interests of investors by establishing a sound governance structure and efficient decision-making mechanism.

During the reporting period, the company completed important adjustments to its governance structure: in accordance with the latest regulations and actual management needs, the company abolished the board of supervisors and the establishment of supervisors, and the relevant supervisory functions have been fully undertaken by the audit committee under the board of directors. The original "Rules of Procedure of the Board of Supervisors", "Supervisors' Remuneration (Allowance) Plan" and other relevant systems of the Board of Supervisors have been abolished accordingly, and the revision of relevant systems and work handover have been completed to ensure a smooth transition and continued effective operation of the corporate governance mechanism.

At the same time, the company adheres to the concept of sustainable development and gradually integrates environmental, social and governance (ESG) requirements into its operations and management. We continue to pay attention to employee growth and protection of rights and interests, and are committed to building a diversified and inclusive development platform; we continue to improve the risk management system and improve the stability and compliance of operations; we actively fulfill our corporate social responsibilities and make due contributions in promoting industrial development and serving public health. In the future, the company will continue to improve its governance structure, strengthen the construction of ESG system, promote the deep integration of corporate governance, social responsibility and sustainable development, and lay a solid foundation for long-term stable development.

2. Daily work of the Board of Directors in 2025

(1) Convening of board of directors meetings

In 2025, the company held a total of 9 board meetings. The company's board of directors strictly abided by the relevant provisions and requirements of the "Company Law", "Company Articles of Association", "Rules of Procedure for Shareholders' Meetings" and "Rules of Procedure for Board of Directors", and made decisions on relevant matters of the 2025 Annual Shareholders' Meeting Information Department of Gonghai Chuang Pharmaceutical Co., Ltd., with standardized procedures. The details are as follows:

Serial number Time of convening Meeting name Proposal reviewed and approved

January 2025 Second Board of Directors

1 1. "Proposal on the postponement of part of the investment projects raised by the initial public offering of stocks" Eighth meeting on the 13th

Proposal on the company’s “2024 General Manager Work Report”
Proposal on the company’s “2024 Board of Directors Work Report”
Proposal on the company’s “Duty Performance Report of the Audit Committee of the Board of Directors in 2024”
Proposal on the company’s “Financial Accounts Report for 2024”
Proposal on the company’s “2025 Financial Budget Report”
Proposal on the company’s “Profit Distribution Plan for 2024”
Proposal on the company’s “Special Report on the Deposit and Actual Use of Raised Funds in 2024”
Proposal on the company’s expected daily related transactions in 2025
Proposal on using part of temporarily idle self-owned funds for cash management-

April 2025 Second Board of Directors

2 10. Discussion on using part of temporarily idle raised funds for cash management. Ninth meeting on the 18th.

case

Proposal on the company’s application for a credit line from financial institutions in 2025
Proposal on the remuneration (allowance) plan for the company’s directors in 2025
Proposal on the compensation plan for the company’s senior managers in 2025
Proposal on the company’s “2024 Annual Report” and its summary
Proposal on the company’s “2024 Internal Control Evaluation Report”
Proposal on the Re-appointment of the Company’s Financial and Internal Control Audit Agency for 2025
Proposal on requesting the general meeting of shareholders to authorize the board of directors to issue stocks to specific objects through simplified procedures
Regarding the purchase of responsibilities for the company and its directors, supervisors, and senior managers, the 2025 Annual Shareholders Meeting Materials of Haichuang Pharmaceutical Co., Ltd.

insurance bill

Proposal on the "Report on the Performance of Supervisory Responsibilities of the Accounting Firm by the Audit Committee of the Board of Directors in 2024"
Proposal on the "2024 Accounting Firm Performance Evaluation Report"
Proposal on self-examination of independence of independent directors
Proposal on convening the company’s 2024 annual shareholders’ meeting April 2025 Second Board of Directors 1. Proposal on the company’s <2025 First Quarter Report>

The 10th meeting on the 25th 2. Announcement on the company’s application for mortgage loans from the bank

Proposal on the company’s “2025 Semi-annual Report” and its summary
Proposal on the review of the company’s “Special Report on the Deposit and Actual Use of Funds Raised in the Half-Year of 2025”

August 2025 The second session of the Board of Directors 3. Proposal on canceling the company's supervisory board and amending the "Articles of Association" on the 13th Eleventh meeting 4. Proposal on formulating, revising and abolishing part of the company's governance system

Proposal on the adjustment of sub-projects of part of the investment projects raised by the initial public offering of stocks
Proposal to convene the first extraordinary general meeting of shareholders in 2025 August 2025 Second Board of Directors 1. Proposal to consider exempting the notice time limit for this meeting

31st Twelfth Meeting 2. Proposal on Review of the Company’s External Donations

Proposal on amending some of the company’s governance systems
Proposal on changing the company’s 2025 financial report and internal control audit mechanism 2025 10 Second Session of the Board of Directors

The thirteenth meeting on March 14th 3. Proposal on the by-election of independent directors of the second session of the Board of Directors

Proposal on adjusting members of some special committees of the second session of the Board of Directors
Proposal on convening the first extraordinary general meeting of shareholders in 2025 2025 10 Second session of the Board of Directors

7 1. Proposal on the company’s “2025 Third Quarter Report”

The 14th meeting on March 30

December 2025 The Second Session of the Board of Directors 1. Proposal on Amending the Articles of Association

The 15th meeting on March 8th 2. Proposal to convene the second extraordinary shareholders’ meeting in 2025 Haichuang Pharmaceutical Co., Ltd. 2025 annual shareholders’ meeting meeting materials

December 2025 Second Board of Directors

9 1. Proposal on the postponement of part of the investment projects raised by the initial public offering of stocks The 16th meeting on the 24th

(2) The board of directors convenes the shareholders’ meeting and implements the resolutions of the shareholders’ meeting

During the reporting period, the company held a total of 3 shareholders (general meetings). The convening, holding and voting procedures of the meetings complied with the provisions of laws, regulations, normative documents and the Articles of Association. The details are as follows:

Serial number Time of convening Meeting name Proposal reviewed and approved

Proposal on the company's "2024 Board of Directors Work Report"
Proposal on the company’s “2024 Work Report of the Board of Supervisors”
Proposal on the company’s “Financial Accounts Report for 2024”
Proposal on the company’s “2025 Financial Budget Report”
Proposal on the company’s “Profit Distribution Plan for 2024”
Proposal on the remuneration (allowance) plan for the company's directors in 2025, 2025 May 2024 7. Proposal on the remuneration (allowance) plan for the company's supervisors in 2025, the General Assembly on 9 March 8. Proposal on the company's "2024 Annual Report" and its summary
Proposal on the renewal of the company’s financial and internal control audit institutions for 2025
Proposal on requesting the general meeting of shareholders to authorize the board of directors to issue stocks to specific objects through simplified procedures
Proposal on purchasing liability insurance for the company and its directors, supervisors and senior managers
Proposal on canceling the company’s board of supervisors and amending the “Articles of Association”
Proposal on amending some of the company’s governance systems
Regarding changes to the company’s 2025 financial report and internal control audit October 2025 First time in 2025

2 Institutional Proposal

Extraordinary general meeting of shareholders on March 30

Proposal on the adjustment of sub-projects of part of the investment projects raised by the initial public offering of stocks
Proposal on the election of independent directors for the second session of the Board of Directors

December 2025 Second time in 2025

3 1. Proposal on amending the Articles of Association

Extraordinary shareholders meeting on 24th

Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials

In 2025, the company's board of directors strictly complied with the provisions and requirements of the Company Law, the Articles of Association and the Rules of Procedure of the Board of Directors, strictly followed the resolutions and authorizations of the shareholders (general meeting), conscientiously performed its duties, and fully implemented the relevant matters resolved by the company's shareholders (general meeting).

(3) Performance of duties of each special committee of the board of directors

The company's board of directors has four special committees: the Remuneration and Assessment Committee, the Nomination Committee, the Strategy and ESG Committee and the Audit Committee.

A total of 7 special committees will be held in 2025, including:

In 2025, the Audit Committee will be held 5 The Audit Committee had a detailed understanding of the company's financial status and operating conditions, supervised and evaluated the audit work, and implemented effective guidance and supervision on the company's financial reports, related transactions, internal controls, etc.; it convened the Remuneration and Assessment Committee once, and the Remuneration and Assessment Committee reviewed the annual remuneration plan for the company's directors and senior managers, and supervised the implementation of the company's remuneration system; it convened the Nomination Committee once, and the Nomination Committee conducted a prudent assessment and review of the qualifications, independence, professional background and performance capabilities of the company's independent director candidates.

(4) Duty performance of independent directors

During the reporting period, the company’s independent directors performed their duties diligently and diligently in accordance with the requirements of laws, regulations and internal rules such as the Company Law, Articles of Association, Rules of Procedure of the Board of Directors, and Working System of Independent Directors, and effectively fulfilled their obligations of loyalty and diligence. The independent directors actively participated in the meetings of the board of directors and its special committees held by the company, carefully reviewed the meeting materials before the meeting, conducted in-depth analysis and independent and prudent voting on various proposals based on their own professional judgment, and expressed independent opinions on major matters of the company. Independent directors continue to pay attention to the company's operating status, financial management, internal control, related transactions and other matters, have an in-depth understanding of the company's operations, and maintain effective communication with the board of directors, management and internal audit department. In the process of performing their duties, independent directors always maintain full independence and objectivity, especially on key matters such as the company's major decisions, related transactions, director nomination and remuneration, from the perspective of safeguarding the overall interests of the company and the legitimate rights and interests of all shareholders (especially small and medium-sized shareholders), express opinions independently and impartially, and effectively play the role of supervision and checks and balances.

In accordance with relevant regulations, the independent directors submitted the "Independent Directors' 2025 Annual Work Report" to the board of directors, comprehensively reporting on their performance of their duties this year, and will take office at the 2025 annual shareholders' meeting.

3. Key tasks of the Board of Directors in 2026

Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials

In 2026, the company's board of directors will continue to abide by laws, regulations and the responsibilities entrusted by the "Articles of Association", with the core goal of improving corporate governance and core competitiveness, give full play to strategic leadership and scientific decision-making, and focus on the following work:

The board of directors will continue to pay attention to industry development trends and market dynamics, conduct in-depth research with a forward-looking perspective and optimize the company's mid- and long-term development strategies in a timely manner. By improving the operational efficiency of the board of directors and various special committees, we ensure the scientificity and prudence of major operations, investments and management decisions, promote the steady progress of the company's innovative drug research and development and commercialization process, and create long-term value for all shareholders.

The board of directors will be committed to further improving the corporate governance structure and internal control system, and optimizing various rules of procedure and work processes. Strictly follow the listing rules and relevant laws and regulations to ensure full compliance of the company's operations. We will continue to strengthen information disclosure management to ensure that information disclosure is timely, fair, true, accurate and complete, and effectively safeguard the right to know of all investors.

At the same time, the board of directors will guide and urge the management to carry out investor relations management in a more proactive manner. Through various forms such as regular reporting performance briefings, road shows, reception surveys, and online interactive platforms, we maintain smooth and transparent two-way communication with investors, respond to market concerns in a timely manner, convey the company's value, and consolidate and enhance the company's good image in the capital market and investor trust.

Board of Directors of Haichuang Pharmaceutical Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Haichuang Pharmaceutical Co., Ltd. on May 15, 2026

Proposal 3. Proposal on the company's "2025 Financial Final Accounts Report"

Dear shareholders and shareholders’ agents:

Based on the company's overall operations in 2025 and combined with the 2025 audit report issued by ShineWing Certified Public Accountants (Special General Partnership), the company prepared the "2025 Financial Final Accounts Report". Please see Appendix 2 for the specific content.

Board of Directors of Haichuang Pharmaceutical Co., Ltd.

May 15, 2026

Attachment 2: "2025 Financial Final Accounts Report"

Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials

Attachment 2

Haichuang Pharmaceutical Co., Ltd.

2025 Annual Financial Accounts Report

The consolidated and company balance sheet of Haichuang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") on December 31, 2025, the consolidated and company income statement, the consolidated and company cash flow statement, the consolidated and company changes in shareholders' equity statements for 2025, and the notes to the relevant financial statements have been audited by ShineWing Certified Public Accountants (Special General Partnership), and a standard unqualified audit report has been issued. The audit conclusion is that the financial statements are prepared in all material aspects in accordance with the provisions of the Accounting Standards for Business Enterprises, and fairly reflect the company's consolidated and parent company's financial status as of December 31, 2025, as well as the consolidated and parent company's operating results and cash flows in 2025.

1. Main financial data and financial indicators

Unit: RMB 10,000 for the current period

Same as last year

Project 2025 2024 Increase or decrease in 2023

(%)

Operating income 2,046.99 36.68 5,480.11 - Net profit attributable to shareholders of the parent company -13,725.26 -19,949.57 Not applicable -29,415.84 Deductions attributable to shareholders of the parent company are non-economic

-16,787.17 -21,750.99 Not applicable -32,502.96 Net profit after ordinary gains and losses

Net cash flow generated from operating activities -10,887.83 -18,708.31 Not applicable -25,550.71 Basic earnings per share (yuan/share) -1.39 -2.01 Not applicable -2.97 Basic earnings per share after deducting non-recurring gains and losses

-1.70 -2.20 Not applicable -3.28 share income (yuan/share)

Weighted average return on equity (%) -12.17 -15.59 Not applicable -19.93 Weighted average return after deducting non-recurring gains and losses

-14.88 -17.00 Not applicable -22.02 Average return on equity (%)

Net assets attributable to shareholders of listed companies 106,355.87 119,224.51 -10.79 136,709.03Total assets 130,974.62 136,157.98 -3.81 149,156.51

During the reporting period, the company achieved significant growth in operating income, which was mainly due to the drug sales revenue obtained from the company's first Class 1 new drug, Deuterated Enzalutamide Soft Capsules (Project No.: HC-1119), which was approved for marketing in May 2025.

Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials

In order to rationally plan R&D investment, the company has further optimized its R&D pipeline and accelerated the advancement of key R&D projects to improve the efficiency of fund use. Investments in different stages of R&D projects are different, and R&D expenses have decreased year-on-year. At the same time, the company is in the early expansion stage of drug launch commercialization, and needs to invest more in early market expansion and academic promotion activities, and sales expenses have increased. In addition, share-based payment expenses have decreased due to the expiration of equity incentives and government subsidies related to income have increased compared with the same period of the previous year.
The net profit attributable to shareholders of the listed company was -137.2526 million yuan; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was -167.8717 million yuan, a year-on-year loss of 49.6382 million yuan, a decrease of 22.82%.
During the reporting period, the net cash flow generated from operating activities was -108.8783 million yuan, the inflow from operating activities was 70.9311 million yuan, and the year-on-year income increased by 49.9166 million yuan, mainly due to the increase in drug income and deposits; the cash outflow from operating activities was 179.8093 million yuan, and the year-on-year expenditure decreased by 28.2931 yuan. million, mainly due to the increase in sales expenses and the decrease in R&D expenses during the reporting period.
At the end of the reporting period, total assets were RMB 1,309.7462 million, a decrease of 3.81% from the beginning of the period; owners' equity attributable to the parent company was RMB 1,063.5587 million, a decrease of 10.79% from the beginning of the period, mainly due to the company's continued investment in R&D projects.

2. Main assets, liabilities and owner’s equity

(1) Asset situation

On December 31, 2025, the company's total assets were 1,309,746,200 yuan, a year-on-year decrease of 51,833,600 yuan, or 3.81%. Among them: the company's current assets were 906,337,400 yuan, an increase of 2.35% from the end of 2024, and the company's non-current assets were 4,403,408,900 yuan, a decrease of 15.26% from the end of 2024.

Changes in asset items and the reasons for major changes during the reporting period are as follows:

Unit: RMB 10,000

End of current period End of previous period

End of current period

Number of total assets at the end of the current period Number of total assets at the end of the previous period

The amount is higher

Project name Description Number Proportion of production Number Proportion of production

Changes at the end of each period

(%) (%)

dynamic ratio

Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials

(%)

Mainly due to the continued investment in monetary funds for R&D in the current period 43,817.67 33.46 63,344.39 46.52 -30.83 and the expenditure on the construction of R&D and production bases

The end of this period is the transaction fee for purchase settlement

31,059.49 23.71 21,048.67 15.46 47.56 Assets financed by unexpired structural deposits

Mainly due to prepayments for research and development expenses 724.39 0.55 1,025.62 0.75 -29.37

due to reduced usage

one year

Mainly due to large-amount deposits due in the company

10,915.56 8.33 - - - Non-current assets due within one year

caused by

produce

Other flows Mainly due to value-added tax reserve 3,780.45 2.89 3,051.35 2.24 23.89

Assets due to increase in tax refunds

Other non-current mainly due to changes in the fair value of Shenzhen Hongxin Financial Financing 1,379.72 1.05 703.23 0.52 96.20 Biological shares

Mainly due to the fact that some houses were converted into fixed assets 8,306.05 6.34 543.99 0.40 1,426.88 for construction in progress.

Mainly used to convert some houses under construction into fixed houses 26,735.67 20.41 31,450.41 23.10 -14.99

Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials

Right-of-use assets Mainly right-of-use assets 561.07 0.43 867.85 0.64 -35.35

Products due to depreciation and amortization

Intangible assets 3,107.80 2.37 3,056.09 2.24 1.69

Mainly due to the company’s large deposits and other non-current

250.58 0.19 10,982.31 8.07 -97.72 Liquid assets due within one year

caused by

Total assets 130,974.62 100.00 136,157.98 100.00 -3.81

(2) Liabilities

On December 31, 2025, the company's total liabilities were 246.1875 million yuan, an increase of 45.39% from the end of 2024, of which the company's current liabilities were 125.9043 million yuan, a decrease of 14.32% from the end of 2024; the company's non-current liabilities

120.2832 million yuan, an increase of 437.44% compared with the end of 2024.

Changes in liability items during the reporting period and the reasons for major changes are as follows:

Unit: RMB 10,000

Current Period Previous Period End of Current Period

The last share The last share The amount is higher

End of current period End of previous period

Project name Total assets Total assets Changes at the end of the period Description of the situation Number

proportion of proportion dynamic proportion

(%) (%) (%)

Mainly due to bank acceptance notes payable in the current period - - 3,476.54 20.53 -100.00

Accounts payable due to acceptance of all bills due 8,854.75 35.97 9,686.99 57.21 -8.59

Contract liabilities 379.51 1.54 - - - Mainly due to advance receipts for medicines Mainly due to the increase in personnel into employee salaries payable 843.19 3.42 586.27 3.46 43.82

Due to cost increase

Mainly due to the withholding and payment of personal income tax to increase the tax payable 157.80 0.64 122.82 0.73 28.48

caused by addition

Mainly due to the increase in other payables from the deposit in this period 1,973.10 8.01 500.52 2.96 294.21

caused by

Mainly due to long-term loans from ICBC in the current period 10,000.00 40.62 - - -

due to term loan

Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials

Mainly due to lease payments in the current period Lease liabilities 259.08 1.05 583.07 3.44 -55.57

caused by

Total liabilities 24,618.75 100.00 16,933.47 100.00 45.39

(3) Owners’ equity

As of December 31, 2025, the company's total owner's equity was 1,063.5587 million yuan, a decrease of 10.79% from the end of 2024. The reasons for project changes and major changes during the reporting period are as follows:

Unit: RMB 10,000

Change ratio

Owner's equity Closing amount for the current period Closing amount for the previous period Description of the situation (%)

Share capital 9,901.56 9,901.56 -0.00

Capital reserve 259,165.49 258,297.13 0.34

Other comprehensive income -14.71 -2.98 393.51

Mainly due to continued undistributed profits from research and development this year -162,696.47 -148,971.21 9.21

Increase in investment losses attributed to parent company shares

106,355.87 119,224.51 -10.79

Total equity

Minority interests - - Not applicable

Total shareholders’ equity 106,355.87 119,224.51 -10.79

3. Profit and period expenses

Unit: RMB 10,000 Change ratio

Project 2025 2024 Situation Description (%)

Mainly due to the operating income of pharmaceutical sales offices in the current period 2,046.99 36.68 5,480.66

Operating costs 28.28 33.59 -15.80

Taxes and surcharges 90.17 41.13 119.22

Mainly due to sales labor and promotion sales expenses in the current period 3,769.11 1,135.34 231.98

due to increased expenditure

Management expenses 4,246.17 4,214.03 0.76

Mainly due to the increase in research and development expenses during the reporting period 11,270.77 17,403.17 -35.24

Utilization efficiency focuses on promoting optimization and adjustment. 2025 Annual Shareholders Meeting Materials of Haichuang Pharmaceutical Co., Ltd.

product pipeline, due to different investments in the research and development stages of R&D projects - mainly due to the decrease in interest income in the current period and other financial expenses -1,073.29 -40.85

634.89 due to

Mainly due to the increase in government subsidies in the current period: other income 1,621.94 490.86 230.43

Investment income (loss mainly due to decrease in bank deposits and financial management 518.41 914.47 -43.31

Enter "-") Income from change in fair value due to lower yield

Mainly due to the fair holding of Hongxin Biotechnology shares (losses are filled in with "-" 1,016.71 396.28 156.56

due to changes in value

column)

Credit impairment loss (loss

-70.41 -32.47 116.85

Please fill in the column with "-" sign)

3. Operating profit (loss)

-13,635.96 -19,948.15 -31.64

Fill in the column with "-" sign)

Add: Non-operating income 0.01 Not applicable

Less: Non-operating expenses 88.99 0.21 42,278.08 Mainly due to the increase in donation expenses, etc.

4. Total profit (loss

The total amount is filled in with "-" -19,948.35 -31.20

13,724.96

column)

Less: Income tax expense 0.30 1.22 -75.08

5. Net profit (net loss

-13,725.26 -19,949.57 -31.20

Fill in the column with "-" sign)

4. Cash flow situation

Unit: RMB 10,000

Change ratio items 2025 2024 Change amount

(%) Cash generated from operating activities

-10,887.83 -18,708.31 7,820.48 -41.80 Net cash flow

Cash generated from investment activities

-13,970.37 -3,025.04 -10,945.33 361.82 Net cash flow

Cash generated from financing activities - 9,524.07 -405.63 9,929.70

Net cash flow 2,447.97 Exchange rate changes on cash and

-229.44 142.71 -372.15 -260.77 Impact of cash equivalents

Cash and cash equivalents

-15,563.57 -21,996.26 6,432.69 -29.24Net increase

The analysis of changes in cash flow items is as follows:

Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials

The net cash flow generated from operating activities was -108.8783 million yuan, and the net operating flow increased by 78.2048 million yuan year-on-year. This was mainly due to the increase in drug income and deposits, the increase in sales expenses, and the decrease in R&D expenses during the reporting period.
The net cash flow generated from investing activities decreased by RMB 109.4533 million year-on-year, mainly due to the increase in the unexpired and unredeemed amount of structured deposit investments using idle funds during the reporting period.
The net cash flow generated from financing activities increased by RMB 99.297 million year-on-year, mainly due to the addition of long-term bank loans in this period.

Haichuang Pharmaceutical Co., Ltd. 2025 Annual Shareholders Meeting Materials

Proposal 4. Proposal on the company’s “Profit Distribution Plan for 2025”

Dear shareholders and shareholders’ agents:

According to the audit by ShineWing Accounting Firm (Special General Partnership), the company's net profit attributable to shareholders of the listed company in 2025 was -137.2526 million yuan (consolidated statement), and the parent company's net profit was -139.0649 million yuan; as of December 31, 2025, the parent company's cumulative undistributed profit was -1,634.1542 million yuan.

Because the company's accumulated undistributed profits were negative as of December 31, 2025, in order to ensure and meet the company's normal operations and sustainable development needs, the company's profit distribution plan for 2025 is: no cash dividends, no bonus shares, and no capitalization of capital reserve funds.

This proposal has been reviewed and approved at the 17th meeting of the company's second board of directors. It is now submitted to the shareholders' meeting for review. All shareholders and shareholders' agents are requested to review this document.

Board of Directors of Haichuang Pharmaceutical Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Haichuang Pharmaceutical Co., Ltd. on May 15, 2026

Proposal 5. Proposal on the 2026 remuneration (allowance) plan for the company’s directors

Dear shareholders and shareholders’ agents:

In accordance with relevant regulations such as the "Code of Corporate Governance for Listed Companies", the "Stock Listing Rules for the Science and Technology Innovation Board of the Shanghai Stock Exchange", "Working Rules of the Board of Directors' Remuneration and Assessment Committee", and taking into account the actual operating conditions and the economic development level of the industry and region, job responsibilities and annual operating conditions, the Board of Directors' Remuneration and Assessment Committee has formulated the 2026 director remuneration (allowance) plan. The director remuneration (allowance) standards are as follows:

The allowance standard for independent directors is 180,000 yuan per person (before tax) per year, and is paid on an average monthly basis;
Other non-independent directors who concurrently hold administrative positions in the company receive remuneration based on the "Labor Contract" or "Employment Contract" signed between them and the company, their positions in the company and the company's salary management system, and will no longer receive additional director allowances;
Non-independent directors who do not hold administrative positions in the company do not receive remuneration or allowances from the company;
The necessary expenses incurred by directors in attending the company's board of directors and shareholders' meetings and exercising their powers in accordance with the relevant provisions of the Company Law and the Articles of Association shall be reimbursed by the company.

All directors have abstained from voting on this proposal. It is now submitted to the shareholders' meeting for review. All shareholders and shareholders' agents are requested to review this document.

Board of Directors of Haichuang Pharmaceutical Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Haichuang Pharmaceutical Co., Ltd. on May 15, 2026

Proposal 6. Proposal on Re-appointment of the Company’s 2026 Financial Report and Internal Control Audit Institution

Dear shareholders and shareholders’ agents:

The company has fully understood and reviewed the professional competence, investor protection capabilities, independence and integrity of ShineWing Certified Public Accountants LLP (Special General Partnership) (hereinafter referred to as "ShineWing"), and believes that its securities-related business qualifications can meet the qualification requirements for providing financial audit and internal control audit services to the company. It agrees to renew the appointment of ShineWing as the company's 2026 annual financial report and internal control audit agency, and conduct 2026 Annual financial statements and internal control auditing and other related service businesses, the appointment period is one year. The annual audit service fee that the company plans to pay in 2026 is consistent with the previous year (2025), which is 600,000.00 yuan (in capital letters: 600,000 yuan), including financial report audit fees: 500,000.00 yuan (in capital letters: 500,000 yuan), and internal control audit fees: 100,000.00 yuan (in capital letters: 100,000 yuan).

For details, please refer to the "Announcement of Haichuang Pharmaceutical Co., Ltd. on the Re-appointment of the Company's 2026 Financial Report and Internal Control Audit Agency" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on April 25, 2026 (announcement number: 2026-011).

Board of Directors of Haichuang Pharmaceutical Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Haichuang Pharmaceutical Co., Ltd. on May 15, 2026

Proposal 7: Requesting the shareholders’ meeting to authorize the board of directors to issue shares to specific objects through simplified procedures

vote motion

Dear shareholders and shareholders’ agents:

In accordance with the "Registration and Management Measures for Securities Issuance of Listed Companies" (hereinafter referred to as the "Registration Management Measures"), the Shanghai Stock Exchange Listed Companies' Securities Issuance and Listing Review Rules, and the Shanghai Stock Exchange Listed Companies' Securities Issuance and Underwriting Business Implementation Rules, the board of directors requested the shareholders' meeting to authorize the board of directors to choose an opportunity to issue stocks to specific objects with a total financing amount of no more than RMB 300 million and no more than 20% of the net assets at the end of the most recent year. The authorization period is from the date of review and approval at the company's 2025 annual shareholders' meeting to the company's 2026 until the date of the annual shareholders’ meeting.

For details, please refer to the "Announcement of Haichuang Pharmaceutical Co., Ltd. on requesting the shareholders' meeting to authorize the board of directors to issue stocks to specific objects through a simplified procedure" (announcement number: 2026-013) disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on April 25, 2026.

Board of Directors of Haichuang Pharmaceutical Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Haichuang Pharmaceutical Co., Ltd. on May 15, 2026

Proposal 8: Proposal on purchasing liability insurance for the company, directors and senior managers

Dear shareholders and shareholders’ agents:

In order to further improve the company's risk management system, improve the company's corporate governance level, reduce operational risks, promote the company's directors, senior managers and relevant responsible persons to more fully exercise their rights and perform duties within their respective responsibilities, and protect the rights and interests of the company and investors, Haichuang Pharmaceutical Co., Ltd. plans to purchase liability insurance (hereinafter referred to as "Dong Gao Liability Insurance") for the company and all directors, senior managers and related personnel in accordance with the "Code of Corporate Governance for Listed Companies" and other relevant laws, regulations and regulatory provisions.

The specific plans for Donggao Liability Insurance are as follows:

Insured: Haichuang Pharmaceutical Co., Ltd.;

Insured person: the company/all directors, senior managers and other employees acting on behalf of the company; liability limit: each time and cumulative compensation limit is RMB 50 million;

Insurance cost: no more than RMB 500,000 per year (specifically subject to the final quotation data of the insurance company); insurance period: 12 months per period (renew or re-insure when or before the expiration of the insurance contract).

In order to improve the efficiency of decision-making, the board of directors requested the shareholders to authorize the chairman of the company or the authorized agent designated by the chairman to handle matters related to the company's purchase of Dong Gao liability insurance within the above authority (including but not limited to determining the insured, determining the insurance company, determining the insurance amount, insurance premium and other insurance terms, selecting and engaging insurance brokers or other intermediaries, signing relevant legal documents and handling other matters related to insurance, claims, etc.), and to handle related matters such as renewal or re-insurance when (or before) the expiration of the company's Dong Gao liability insurance contract in future years.

Board of Directors of Haichuang Pharmaceutical Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Haichuang Pharmaceutical Co., Ltd. on May 15, 2026

Proposal 9: Proposal on formulating the company's "Remuneration Management System for Directors and Senior Management Personnel"

case

Dear shareholders and shareholders’ agents:

In order to further improve the salary management of directors and senior managers, establish a scientific and effective incentive and restraint mechanism, effectively mobilize the work enthusiasm of the company's directors and senior managers, and improve the company's operating and management efficiency, Haichuang Pharmaceutical Co., Ltd. has formulated the "Remuneration Management System for Directors and Senior Managers" in accordance with the "Company Law of the People's Republic of China", "Listed Company Governance Guidelines" and other relevant laws and regulations, normative documents and the "Articles of Association of Haichuang Pharmaceutical Co., Ltd." and combined with the actual situation of the company. For details, please refer to the company's 2026 The "Remuneration Management System for Directors and Senior Management Personnel" was disclosed on the website of the Shanghai Stock Exchange (www.sse.com.cn) on April 25.

Board of Directors of Haichuang Pharmaceutical Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Haichuang Pharmaceutical Co., Ltd. on May 15, 2026

Listen to: "Independent Directors' 2025 Annual Work Report"

Dear shareholders and shareholders’ agents:

The company's independent directors Zheng Yaguang, Peng Yongchen, Chen Zhen, and Wei Yuquan (retired) summarized various tasks in 2025 and wrote the "Independent Directors' 2025 Annual Work Report", which is now reported to the shareholders' meeting.

For details, please refer to the "2025 Annual Work Report of Independent Directors" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on April 25, 2026.

Please listen.

Board of Directors of Haichuang Pharmaceutical Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Haichuang Pharmaceutical Co., Ltd. on May 15, 2026

Hear: 2026 compensation packages for company senior executives

Dear shareholders and shareholders’ agents:

In accordance with relevant regulations such as the "Code of Corporate Governance for Listed Companies", the "Stock Listing Rules on the Science and Technology Innovation Board of the Shanghai Stock Exchange" and the "Working Rules of the Remuneration and Appraisal Committee of the Board of Directors", combined with the actual operating conditions and the economic development level of the industry and region, the company and the Remuneration and Appraisal Committee of the Board of Directors have formulated the 2026 remuneration plan for the company's senior management personnel, as detailed below:

(1) Principles for formulating salary assessment for senior managers:

The principle of long-term interests is consistent with the company’s long-term value and sustainable and healthy development goals;
The principle of equality of responsibilities and rights, the salary is consistent with the value of the position and the size of the responsibility;
The principles of equal emphasis on incentives and constraints, and reciprocity of rewards and punishments, include improving governance levels in the assessment content.

(2) Composition and payment of remuneration for senior management personnel

The senior management remuneration plan determines the remuneration of senior management personnel based on the administrative positions or responsibilities they assume and the provisions of the company's remuneration management system.

(3) Management organization: The remuneration and assessment committee of the company's board of directors is responsible for formulating and regularly inspecting and supervising the implementation; the remuneration and assessment committee of the board of directors is responsible to the company's board of directors.

(4) Applicable objects: All senior managers of the company.

(5) Applicable period: January 1, 2026 to December 31, 2026.

Directors YUANWEICHEN (Chen Yuanwei), XINGHAILI (Li Xinghai), Dai Li, and YUANWEICHEN (Chen Yuanwei), who are senior managers in the company, have abstained from voting on this proposal. Director Chen Yuanlun, who is acting in concert with YUANWEICHEN (Chen Yuanwei), has abstained from voting. After deliberation and voting by the remaining non-related directors, the proposal was approved.

Please listen.

Board of Directors of Haichuang Pharmaceutical Co., Ltd.

May 15, 2026